Target intelligence / Profile preview

Heat shock protein 90 N-terminal domain (HSP90 NTD) (HSP90 NTD)

Target
HSP90 NTD
Molecular classification
Chaperone [2, 3], ATPase [1, 2], Enzyme [1, 2]
01

Overview

The Heat shock protein 90 (HSP90) N-terminal domain is a highly conserved region of the HSP90 molecular chaperone that contains the essential ATP-binding pocket [1, 2]. This domain is responsible for the ATPase activity that drives the conformational changes necessary for the chaperone's function in protein folding and stabilization [1, 6, 10]. HSP90 facilitates the maturation of hundreds of "client" proteins, including many oncoproteins involved in cell signaling, cell cycle regulation, and apoptosis [2, 3, 11]. In cancer cells, HSP90 is often overexpressed and hijacked to maintain the stability of mutated or overexpressed signaling proteins, a phenomenon known as oncogene addiction [3, 11]. Therapeutic targeting of the N-terminal domain involves small molecules that competitively bind to the ATP pocket, thereby inhibiting the chaperone cycle [1, 2, 10]. This inhibition leads to the misfolding and subsequent proteasomal degradation of client proteins, resulting in the simultaneous disruption of multiple oncogenic pathways [2, 3, 10, 12]. While potent in preclinical models, N-terminal inhibitors have faced clinical hurdles such as hepatotoxicity, ocular toxicity, and the induction of a pro-survival heat shock response [2, 7, 12, 14].

Other names
HSP90 amino-terminal domainHSP90 ATP-binding domainN-terminal domain of Heat shock protein 90HSP90 NTD
02

Mechanism of action

Competitive inhibition of the ATP-binding pocket in the N-terminal domain [1, 2, 10], preventing the ATPase-driven chaperone cycle [1, 6, 10] and leading to the proteasomal degradation of client proteins [2, 3, 10, 12].

03

Biological functions

Protein folding [2, 3]Protein stabilization [2, 3]ATP hydrolysis [1, 6, 10]Signal transduction [2, 3, 11]Cell cycle regulation [6, 11]Apoptosis regulation [11]
04

Disease associations

Cancer [2, 3, 10, 11]Neurodegenerative disease [2, 3, 14]Infection [2, 5, 14]Inflammation [5]Cardiovascular disease [3]
05

Safety considerations

Hepatotoxicity [2, 7, 12]Ocular toxicity (visual disturbances) [2, 14]Gastrointestinal distress [2]Fatigue [2]Induction of pro-survival heat shock response [7, 12]
06

Interacting drugs

Geldanamycin [1, 2, 3]

8 more in the full profile.

07

Biomarkers

HSP70 induction [7, 12]Client protein degradation (e.g., HER2, AKT, BCR-ABL) [1, 2, 13]HSF-1 activation [2, 9]

Beyond the preview

Go deeper on Heat shock protein 90 N-terminal domain (HSP90 NTD) (HSP90 NTD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heat shock protein 90 N-terminal domain (HSP90 NTD) (HSP90 NTD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call